Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Oral Copaxone Could Be Studied At Higher Dose After Interim Analysis

Executive Summary

Teva is considering conducting a Phase III trial evaluating a higher dose of oral Copaxone (glatiramer acetate) after an interim analysis of Teva's Phase III study of the oral formulation suggested that the trial will not meet its endpoints.

You may also be interested in...



Ivax/Serono Oral MS Therapy Mylinax Efficacy Trials Planned For 2004

Ivax and Serono hope to launch pivotal trials for their oral multiple sclerosis therapy Mylinax (cladribine) in late 2004

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS038559

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel